Application No.: known Docket No.: BB1321-1

Page 4

### Remarks

Applicants respectfully submit that the amendment to the Specification only corrects obvious typographical errors. Furthermore, applicants submit that newly added claims more clearly and distinct recite that which applicants consider to be their invention, and are adequately supported by the original disclosure.

No new matter is believed to be at issue. Entry of the amendments and early favorable consideration of the claims on the merits are hereby respectfully requested.

Respectfully submitted,

KENING LI

ATTORNEY FOR APPLICANTS

REGISTRATION NO. 44,872 TELEPHONE: (302) 992-3749

FACSIMILE: (302) 892-1026

Dated: 07/11/2w/

Page 5

## **VERSION WITH MARKINGS TO SHOW CHANGES MADE**

In showing the changes, deleted material is shown as bolded brackets and stricken through, and inserted material is shown underlined.

#### **IN THE SPECIFICATION:**

Please replace the following paragraphs:

## Paragraph starting at page 6, line 15:

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by nucleic acid fragments that do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid fragment which result in the production of a chemically equivalent amino acid at a given site, but do not affect [effect] the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Consequently, an isolated polynucleotide comprising a nucleotide sequence of at least one of [60] 30 (preferably at least one of 40, most preferably at least one of [30] 60) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of (a) SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 and the complement of such nucleotide sequences, and/or (b) SEQ ID NOs:19, 21, 23, 53, 55, and 57 and the complement of such nucleotide sequences may be used in methods of selecting an isolated polynucleotide that affects the expression of an LPAAT isozyme polypeptide in a host cell. A method of selecting an isolated polynucleotide that affects the level of expression of a polypeptide in a host cell (eukaryotic, such as plant or yeast, prokaryotic such as bacterial, or viral) may comprise the steps of: constructing an isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention; introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; measuring the level a polypeptide in the host cell containing the isolated polynucleotide;

Application No.: known Docket No.: BB1321-1

Page 6

and comparing the level of a polypeptide in the host cell containing the isolated polynucleotide with the level of a polypeptide in a host cell that does not contain the isolated polynucleotide.

# Paragraph starting at page 8, line 28:

"Codon degeneracy" refers to divergence in the genetic code permitting variation of the nucleotide sequence without affecting [effecting] the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell, it is desirable to design the nucleic acid fragment such that its frequency of codon usage of the host cell.